Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Tesamorelin44 residuesYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARLEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Egrifta, Egrifta SV, Egrifta WR
Eighteen percent visceral fat reduction in 26 weeks, confirmed across 816 patients in the TRIM Phase 3 trials (Falutz et al. 2010)[1]. The tesamorelin peptide (Egrifta) is an FDA-approved GHRH analog that triggers pulsatile GH release, targeting visceral adipose tissue. Subcutaneous bioavailability sits below 4%, yet receptor-level potency still produces reliable IGF-1 elevation and consistent abdominal fat loss. Antibody formation in roughly 50% of patients on continuous dosing is the main long-term limitation; 10 to 15% develop neutralizing antibodies that reduce response. Adults with stubborn visceral belly fat, HIV lipodystrophy patients, and those pursuing GH optimization through the most potent available GHRH analog are the primary users.
Eighteen percent less visceral fat at six months. That's the headline number from the TRIM trials, and it holds up across 816 participants in a double-blind, placebo-controlled Phase 3 program. The tesamorelin peptide (trade name Egrifta SV, also marketed as Egrifta WR, compound code TH9507 (CAS 218949-48-5)) is a synthetic 44-amino-acid GHRH analog with an added trans-3-hexenoic acid modification that extends stability beyond native GHRH. The mechanism is straightforward. Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs, producing pulsatile GH release rather than flat tonic elevation. That GH pulse drives hepatic IGF-1 production, and IGF-1 mediates the downstream lipolysis, targeting visceral adipose depots. Subcutaneous bioavailability runs below 4% per the FDA label (Section 12.3), yet the receptor-level response is potent enough to produce measurable body composition changes. In clinical practice, the FDA approved tesamorelin in 2010 for HIV-associated lipodystrophy with excess visceral adipose tissue. The TRIM trial data [1] showed a mean visceral fat reduction of 26 cm squared versus a 3.8 cm squared gain on placebo, with waist circumference dropping 2.5 cm. Beyond HIV, the off-label use has expanded considerably. Stanley and colleagues published a 2019 Lancet HIV trial [2] showing 35% of patients achieved liver fat below 5% at 12 months, establishing a potential NAFLD benefit. Baker et al. [3] demonstrated improved executive function in older adults and MCI patients after 20 weeks of GHRH treatment in a 152-person RCT. Community dosing mirrors the FDA label at 2 mg daily subcutaneous abdomen, with most protocols running 12 to 26 weeks followed by a rest period. Compared to sermorelin, which lost its FDA approval in 2008 for manufacturing reasons, tesamorelin carries the only active FDA approval among GHRH analogs. Half-life is longer too: 26 to 38 minutes versus sermorelin's 10 to 20 minutes.
Tesamorelin binds the growth hormone releasing hormone receptor (GHRH-R) on anterior pituitary somatotroph cells. Tesamorelin is a modified analog of endogenous GHRH(1-44)NH2 with a trans-3-hexenoic acid group attached to the tyrosine at position 1. That chemical modification protects against enzymatic degradation and improves the molecule's half-life from seconds to roughly 26 to 38 minutes at steady state (FDA label Section 12.3). Once GHRH-R activates, the intracellular signaling cascade mirrors what happens with natural GHRH. Cyclic AMP rises in somatotrophs, calcium channels open, and GH vesicles release into the bloodstream. The resulting GH pulse peaks quickly; Tmax occurs at approximately 9 minutes post-injection. GH then stimulates hepatic IGF-1 synthesis. IGF-1 is the workhorse molecule for tissue-level effects: lipolysis in visceral adipose, protein synthesis in muscle, collagen turnover, and hepatic fat metabolism. The visceral fat selectivity is a GH-pathway feature, not a tesamorelin-specific property. GH-driven lipolysis preferentially targets visceral adipose tissue because visceral fat cells express higher densities of GH receptors and beta-adrenergic receptors than subcutaneous fat. The TRIM trials confirmed this: visceral fat dropped 18% while subcutaneous fat remained unchanged. Because tesamorelin works through the pituitary, the hypothalamic feedback loop stays intact. Somatostatin is the natural brake on GH secretion. This self-regulating mechanism is why tesamorelin produces physiological pulsatile GH release rather than the flat supraphysiological elevation seen with exogenous HGH.
FDA-approved GHRH analog with strong Phase 3 RCT data (n=816, TRIM trials). ~18% VAT reduction at 26 weeks confirmed. NAFLD benefit in HIV shown in Lancet HIV 2019 RCT (35% achieved liver fat <5% at 12 months). Cognitive benefit (executive function in MCI and healthy older adults) shown in 2012 RCT (n=152). 2024 INSTI-era study (n=61)[4] confirmed efficacy persists on modern ART regimens with no exacerbation of glycemic control. Active Phase 3 trial (TRIUMPH, NCT06554717) exploring exercise adjunct in HIV. Mechanism well-established: GHRH analog → pulsatile GH release → IGF-1 rise → visceral lipolysis. SC bioavailability <4% but potent at receptor level.
Falutz et al. 2010 (PMID 20101189): pooled Phase 3 TRIM trials (n=816), double-blind RCT, 26 weeks: VAT −26.0 cm² vs. +3.8 cm² placebo; waist circumference −2.5 cm vs. placebo. Stanley et al. 2019 (PMID 31611038) Lancet HIV for NAFLD indication.
FDA approval limited to HIV-associated lipodystrophy; off-label use for general visceral fat reduction or cognition lacks large RCTs in non-HIV populations. SC bioavailability <4% means batch-to-batch potency variation in compounded product is clinically meaningful. Antibody formation in ~50% of patients (non-neutralizing in most; ~10–15% may see reduced efficacy). IGF-1 monitoring burden. No data in large non-HIV populations.
Regarded as the most targeted visceral fat peptide available. Community broadly follows FDA dosing (2 mg/day SC abdomen). Off-label use well-established among non-HIV users for belly fat reduction and GH optimization. Strong overlap between clinical expectations and community-reported outcomes. Primary criticisms: cost of compounded product, abdominal-only injection requirement, and IGF-1 testing burden.
Community dosing mirrors the FDA-approved 2 mg/day protocol. Reported outcomes for visceral fat reduction closely match TRIM trial data. Off-label cognitive and GH optimization uses are an extension of the clinical mechanism, not a contradiction. Main divergence: community runs 3–6 month cycles with breaks whereas the FDA label supports ongoing continuous treatment.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mg | Daily |
| Moderate | 2mg | Daily |
| Aggressive | 2mg | Daily |
With a 5 mg vial and 2 mL bacteriostatic water, you get 2.5 mg/mL (2500 mcg/mL). At that concentration: 2000 mcg (the standard dose) is 80 units on a U-100 insulin syringe. That's 0.8 mL, so you'll use close to half the syringe. Each 5 mg vial gives you 2.5 daily doses at 2 mg per day. With a 2 mg vial and 2 mL BAC water, you get 1 mg/mL. A full 2 mg dose requires the entire reconstituted vial in one shot. Not practical for multi-day use; the 5 mg vial is the better choice. Inject into abdominal subcutaneous fat only. The FDA label specifies this, and the clinical data was collected this way. Don't rotate to thigh or arm. Rotate within the abdomen, at least 2 cm from the umbilicus. The non-obvious thing: your IGF-1 check at four to six weeks isn't optional. If IGF-1 hasn't risen, either the peptide is degraded, your injection technique is off, or you've drawn a bad batch from the compounder. Don't run a full 26-week cycle without confirming the molecule is actually working. Pre-bed injection is the community preference for off-label use because it matches the natural nocturnal GH surge. FDA trials used morning dosing. Either works; consistency matters more than timing.
Anti-tesamorelin antibodies form in ~50% of patients during continuous treatment per TRIM trial immunogenicity data. Most are non-neutralizing and do not reduce efficacy, but a subset (~10–15%) form neutralizing antibodies that blunt VAT reduction response. Cycling (typically 26 weeks on, 4–8 weeks off) allows antibody titers to decline, restoring receptor-level sensitivity on re-challenge. Cycling also limits continuous IGF-1 elevation and associated insulin resistance, and enables structured glucose monitoring intervals. The FDA label supports ongoing treatment without mandatory cycling: community and clinic protocols add rest periods for practical adherence and cost reasons.
Or use the universal Peptide Calculator for any peptide.
Expected: ~18% VAT reduction and −2.5 cm waist circumference at 26 weeks (TRIM Phase 3, n=816). Liver fat reduction in NAFLD patients (35% achieved liver fat <5% at 12 months, Stanley 2019). IGF-1 rise at 4–6 weeks confirms GH axis activation.
Monitor: IGF-1 at baseline and 4–6 weeks, then every 6 months. Fasting glucose and HbA1c at baseline, then every 3–6 months. Waist circumference or DEXA/CT at baseline and 6 months. If IGF-1 >ULN: reduce or hold dose.
You'll need a 5 mg tesamorelin vial (lyophilized powder), bacteriostatic water, a mixing syringe with an 18-gauge needle for reconstitution, and a U-100 insulin syringe (29 to 31 gauge, half-inch needle) for injection.
Draw 2 mL of bacteriostatic water into the mixing syringe. Inject slowly down the inside wall of the vial. Do not shake. Let it sit or gently swirl until the powder dissolves completely. This gives you 2.5 mg/mL. The solution should be clear and colorless; discard if cloudy or discolored.
Using a fresh U-100 insulin syringe, draw 80 units for the standard 2000 mcg dose. That's 0.8 mL at the 2.5 mg/mL concentration.
Abdominal subcutaneous fat, at least 2 cm away from your navel. Avoid scar tissue and bruised areas. Rotate sites with each injection to prevent localized lipoatrophy.
Pinch a fold of skin, insert the needle at a 45 to 90 degree angle, inject slowly, hold for 5 seconds, then withdraw.
Store reconstituted vials refrigerated at 2 to 8 degrees Celsius. Use within 28 days. Keep unreconstituted vials refrigerated as well.
Pre-bed works well for off-label use (matches nocturnal GH pulse). Morning dosing was used in FDA trials. Pick one time and stay consistent.
Classic GHRH + GHRP dual-pathway stack. Tesamorelin provides the GHRH signal; ipamorelin provides the GHRP pulse: co-administration produces synergistic GH release larger than either alone. Ipamorelin preferred as GHRP due to clean profile (no cortisol, prolactin, or appetite co-stimulation).
Inject both simultaneously or within 5 minutes. Tesamorelin 2000 mcg + ipamorelin 200–300 mcg, once daily SC abdomen.
Alternative GHRP for stronger GH pulse amplitude. Generates a larger GH spike than ipamorelin but also raises cortisol and prolactin modestly. Used when maximum GH pulse is the goal and cortisol co-stimulation is acceptable.
Tesamorelin 2000 mcg + GHRP-2 100–200 mcg, once daily pre-bed SC abdomen.
Most potent GHRP available; produces the largest GH pulse per injection. Combined with tesamorelin for maximum GH axis activation in experienced users. Desensitization occurs faster than ipamorelin: typically cycled 4–8 weeks on, 4 weeks off.
Tesamorelin 2000 mcg + hexarelin 100–200 mcg, once daily SC abdomen. Short cycles only.
GLP-1 agonist + GHRH analog for dual-mechanism fat reduction. GLP-1 addresses subcutaneous and total body fat via appetite/insulin pathway; tesamorelin targets visceral fat specifically via GH pathway. Used in some telehealth clinic protocols for significant metabolic syndrome.
Both tesamorelin and exogenous HGH elevate IGF-1. Combination risks supraphysiological IGF-1 levels, worsened insulin resistance, peripheral edema, and acromegaly-like effects with prolonged use. No clinical or community rationale for combining: choose one GH pathway strategy.
Do not combineBoth significantly raise GH and IGF-1 through complementary mechanisms (GHRH vs. ghrelin receptor). Combination produces excessive IGF-1 elevation and compounded insulin resistance risk. Glucose and metabolic effects are additive. Use one at a time.
Do not combineBoth are GHRH analogs: redundant mechanism. Both occupy GHRH receptors and produce pulsatile GH release. Combining two GHRH analogs does not increase efficacy and may cause receptor saturation and unnecessary IGF-1 burden.
Pricing updated 2026-04-09
Glucose management is the most important safety concern with tesamorelin. GH-mediated insulin resistance is a class effect of all GHRH analogs, and the FDA label includes specific warnings about new-onset diabetes and glucose intolerance. Fasting glucose and HbA1c must be monitored at baseline, then every three to six months during treatment. A fasting glucose above 126 mg/dL or HbA1c above 6.5% means stopping or significantly adjusting the protocol. Pre-diabetic users and those with metabolic syndrome carry higher risk. The 2024 INSTI-era study (n=61)[4] confirmed that tesamorelin on modern ART regimens did not exacerbate glycemic control, but that data applies to the HIV population specifically. Active malignancy is an absolute contraindication. Tesamorelin raises IGF-1, and IGF-1 promotes cell proliferation. The FDA label explicitly contraindicates use in patients with active or recurrent cancer. Newly diagnosed malignancy during treatment requires immediate discontinuation. This is not a theoretical concern; it's a black-box-level warning. Antibody formation occurs in approximately 50% of patients on continuous dosing per TRIM trial immunogenicity data. Most antibodies are non-neutralizing and don't reduce clinical effect. A subset of 10 to 15% develop neutralizing antibodies that blunt the VAT reduction response. Signs include declining IGF-1 despite consistent dosing and plateau or reversal of fat loss after initial progress. Cycling (26 weeks on, 4 to 8 weeks off) allows antibody titers to decline and typically restores responsiveness on re-challenge. Injection site reactions are common in the first week: redness, pain, and induration at the abdominal injection site. The FDA label specifies abdominal subcutaneous injection only for this indication. Repeated injection into the same small area can cause localized lipoatrophy (skin dimpling) because tesamorelin triggers local lipolysis. Systematic site rotation across the abdomen prevents this. Avoid the area within 2 cm of the umbilicus and any scarred or bruised skin. Joint pain and peripheral edema affect some users in the first two to four weeks as IGF-1 rises and fluid retention increases. Community reports describe this as self-resolving in most cases. If symptoms persist beyond four weeks, reducing the dose to 1 mg per day usually resolves them. NSAIDs help short-term for joint pain; leg elevation helps for lower extremity edema. Pregnancy is contraindicated due to potential fetal harm per the FDA label. Breastfeeding lacks sufficient safety data. Patients with disruption of the hypothalamic-pituitary axis from hypophysectomy, pituitary tumor, or pituitary surgery should not use tesamorelin, as the mechanism requires functional pituitary somatotrophs. Known hypersensitivity to tesamorelin or mannitol (used as an excipient in the formulation) is a contraindication. When to see a doctor: persistent edema beyond four weeks, fasting glucose above 126 mg/dL, joint pain unresponsive to dose reduction, any new or worsening mass or tumor, or signs of glucose intolerance.
Verify Tesamorelin dosing and safety with a second opinion
Tesamorelin is an FDA-approved molecule (Egrifta SV, Egrifta WR) but most off-label community use is via compounded versions from 503A/503B compounding pharmacies, not commercially manufactured Egrifta. Compounded peptides vary in purity, concentration accuracy, and sterility. SC bioavailability <4% means potency is highly sensitive to peptide integrity; degradation or incorrect concentration directly impacts dosing. FDA has taken enforcement action against compounding pharmacies for peptides in general (2024 503A bulk list enforcement activity). Most reputable US telehealth providers use licensed 503A/503B compounders with COAs.
| Test | When | Target |
|---|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | Baseline; 4–6 weeks into treatment; every 6 months thereafter | Age-adjusted normal range; generally <250 ng/mL for adults under 50; consult lab-specific age/sex reference ranges |
| Fasting Glucose | Baseline; 6–8 weeks; every 3 months | Fasting <100 mg/dL normal; 100–125 pre-diabetic; ≥126 diabetic |
| HbA1c | Baseline; every 3–6 months | <5.7% normal; 5.7–6.4% pre-diabetic; ≥6.5% diabetic |
| Waist Circumference | Baseline; monthly during active treatment | Reduction of ≥2 cm from baseline at 3 months expected for responders |
| Liver Enzymes (ALT, AST) | Baseline; at 3 and 6 months if using for NAFLD/liver fat indication | — |
| Lipid Panel (Triglycerides, LDL, HDL) | Baseline; 6 months | — |
Confirms GH axis activation. If IGF-1 not rising, peptide is inactive or injection technique is off. If above ULN, dose must be reduced or held.
GH-mediated insulin resistance is a known class effect of GHRH analogs. Early detection prevents progression to clinical hyperglycemia.
Longitudinal glycemic control marker. More sensitive than single fasting glucose for tracking trend over a treatment cycle.
Primary practical efficacy measure for VAT reduction. Correlates with CT/MRI VAT changes at population level.
Hepatic benefit shown in Stanley 2019 and INSTI-era 2024 data. Monitoring liver enzyme trends confirms or refutes hepatic response.
HIV-associated lipodystrophy includes dyslipidemia. Triglycerides often improve with VAT reduction. Confirms metabolic benefit beyond VAT in off-label users.
GH and IGF-1 levels begin to rise. Mild injection site reactions may occur. No visible body composition changes yet.
IGF-1 stabilizes at elevated levels. Improved sleep quality and recovery often reported. Early visceral fat mobilization begins.
Measurable reductions in visceral adipose tissue. Clinical trials showed significant VAT decrease by week 12. Waist circumference begins decreasing.
Phase III trials demonstrated ~18% visceral fat reduction at 26 weeks. Trunk fat and waist circumference significantly reduced. Lipid profiles may improve.
Sustained visceral fat reduction with continued use. NAFLD trial showed 35% of patients achieved liver fat below 5% at 12 months. Fibrosis progression significantly slowed.
Weeks 1 to 2: GH pulses ramp up and IGF-1 begins climbing toward a new steady state. Sleep quality often improves within the first week. No visible fat changes yet. Expect injection site redness and pain, mild water retention in hands and feet, and possibly some joint stiffness. These injection site reactions are most common in the first week and typically diminish. Weeks 3 to 6: IGF-1 reaches its new raised plateau, generally 50 to 100% above baseline. This is your confirmation window; get IGF-1 checked at four to six weeks. Sleep improvement stays consistent. Some users notice their waistband fitting slightly looser. Energy and recovery start picking up. Injection site reactions have usually calmed down. Check fasting glucose, because peripheral edema should be resolving by now. Weeks 6 to 12: Measurable visceral fat reduction begins showing up on imaging. TRIM trial data showed a 17 to 25 cm squared VAT decrease at this stage. Waist tape readings start confirming what you can see in the mirror, typically 1 to 2 cm reduction. Most acute side effects have resolved by now. Glucose monitoring remains important. Months 3 to 6: This is the peak response window. The TRIM Phase 3 trials documented approximately 18% visceral fat reduction at 26 weeks. Trunk fat and waist circumference drop significantly. Triglycerides and lipid profiles may improve. A 2024 INSTI-era cohort [4] showed 31% relative hepatic fat reduction. Body recomposition results are at their most visible. A minority of users may notice response blunting from antibody formation at this stage. Months 6 to 12: Continued use maintains the visceral fat reduction, but the NAFLD trial is where the long game pays off: 35% of patients achieved liver fat below 5% at 12 months (Stanley et al. 2019)[2], and fibrosis progression slowed significantly. Most community protocols include a break at six months, cycling off for four to eight weeks before re-challenging. This typically restores responsiveness if antibody-related blunting has occurred. Glucose management is the primary ongoing monitoring concern; check HbA1c at minimum.
GH pulses increase; IGF-1 begins rising toward new elevated steady state. Injection site reactions (redness, pain, induration) common in first week.
Sleep quality often improves within the first week. No visible fat changes. Some note mild water retention in hands/feet. Joint stiffness possible.
IGF-1 reaches new elevated plateau (~50–100% above baseline). Visceral fat mobilization begins at cellular level via GH-mediated lipolysis. Check IGF-1 at 4–6 weeks.
Sleep quality consistently improved. Some notice waistband fitting slightly looser. Energy and recovery improving. Injection site reactions usually diminishing.
Significant VAT reduction on CT/MRI imaging at 12 weeks (TRIM trial data: −17 to −25 cm² at this stage). Waist circumference begins measurably decreasing.
Visible abdominal changes: "visceral fullness" reducing. Waist tape showing 1–2 cm reduction. Users report improved definition despite no other protocol changes.
~18% VAT reduction at 26 weeks per TRIM Phase 3 trials. Trunk fat and waist circumference significantly reduced. Triglycerides and lipid profiles may improve. 31% relative hepatic fat reduction in 2024 INSTI cohort (PMID 38905488).
Most dramatic body recomposition results. Users report 1–3 cm waist circumference reduction. Abdominal definition noticeably improved. Antibody formation may blunt response in a minority at this stage.
NAFLD trial showed 35% achieved liver fat <5% at 12 months. Fibrosis progression significantly slowed. Continued VAT suppression with sustained use. VAT tends to return toward baseline within 6–12 months of stopping.
Users continuing long-term note sustained results. Some experience response blunting (antibodies). Most community protocols include a break at 6 months and re-challenge, which typically restores responsiveness.
Source: Egrifta FDA label Section 12.3: mean t1/2 26 min (healthy) and 38 min (HIV patients) after 14-day SC dosing; single-dose t1/2 8-11 min. Using steady-state mean of ~32 min (0.53h)
Loading the interactive decay curve.
Tesamorelin is FDA-approved (NDA 022505) under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The original approval came in November 2010; the most recent label update is dated 2025. This is one of a very small number of peptides with full FDA approval, Phase 3 RCT data, and an active commercial product. Commercially manufactured Egrifta SV and Egrifta WR are available through specialty pharmacies with a prescription. Brand pricing runs approximately $3,085 per month at GoodRx rates without insurance, or roughly $41,000 per year list price. Patient assistance programs exist (Prescription Hope reports approximately $70 per month for qualifying patients). Off-label use for general visceral fat reduction, body recomposition, or cognitive support requires a prescription from a licensed provider. Most off-label users access tesamorelin through compounded formulations from licensed 503A or 503B pharmacies, typically at $150 to $300 per month. The FDA took enforcement actions against compounding pharmacies for peptides broadly in 2024. Tesamorelin is not currently on the 503A bulk drug substance list for general compounding, which creates a regulatory gray area for non-HIV use. WADA prohibits all growth hormone releasing factors including tesamorelin for competitive athletes. This content is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider before using any peptide.
Peptide Schedule Research TeamReviewed Apr 202614 Citations
